Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Other Non-Current Assets (2020 - 2025)

Cytek Biosciences' Other Non-Current Assets history spans 6 years, with the latest figure at $6.7 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 40.87% year-over-year to $6.7 million; the TTM value through Dec 2025 reached $6.7 million, up 40.87%, while the annual FY2025 figure was $6.7 million, 40.87% up from the prior year.
  • Other Non-Current Assets reached $6.7 million in Q4 2025 per CTKB's latest filing, up from $4.5 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $6.7 million in Q4 2025 to a low of $30000.0 in Q2 2024.
  • Average Other Non-Current Assets over 5 years is $2.8 million, with a median of $2.9 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: plummeted 99.02% in 2024, then skyrocketed 14283.87% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.3 million in 2021, then soared by 123.52% to $2.9 million in 2022, then tumbled by 88.58% to $331000.0 in 2023, then skyrocketed by 1337.76% to $4.8 million in 2024, then surged by 40.87% to $6.7 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Other Non-Current Assets are $6.7 million (Q4 2025), $4.5 million (Q3 2025), and $4.6 million (Q1 2025).